Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
05 December 2024 - 1:01AM
Edgar (US Regulatory)
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of December 2024
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
AstraZeneca appoints Iskra Reic EVP International
4 December 2024
AstraZeneca appoints Iskra Reic as Executive Vice President,
International
AstraZeneca today announced the appointment of Iskra Reic as
Executive Vice President (EVP), International with responsibility
for overall strategy and driving sustainable growth across this
broad region. This encompasses China, Asian and Eurasian markets,
Middle East & Africa, Latin America, Australia & New
Zealand.
Having joined the Company in 2001, Iskra has held leadership
positions across Central & Eastern Europe, Eurasia, Middle East
& Africa. She was appointed EVP for Europe & Canada in 2017
and joined AstraZeneca's Senior Executive Team. Most recently,
Iskra launched the Company's Vaccines and Immune Therapies unit,
successfully establishing it at the forefront of a new and exciting
era of disease prevention. In this role, she was responsible for
the early and late-stage development of the pipeline and portfolio,
including COVID-19 and RSV vaccines and monoclonal antibodies,
strategic partnerships and acquisitions, medical affairs and
commercial operations.
Pascal Soriot, CEO, said: "Iskra is a highly accomplished leader
with extensive international experience across multiple disciplines
and a track record of improving patient access to our innovative
and life-changing medicines. Her experience building partnerships
will be invaluable in taking the fast-growing International region
forward."
Iskra Reic, Executive Vice President, International, said: "It is a
privilege to lead this broad, diverse and innovative region as we
deliver the next wave of science and innovative medicines. I look
forward to working with our partners, stakeholders and colleagues
to improve the lives of millions of people around the world with
our leading medicines and vaccines."
Iskra succeeds Leon Wang who is on extended leave from the Company
while under investigation in China.
Biography of Iskra Reic
Iskra Reic joined AstraZeneca in 2001 and has since held numerous
leadership positions within the Company, including as Executive
Vice-President (EVP) for Europe & Canada and, since 2021, as
EVP, Vaccines & Immune Therapies. She has also held senior
roles across Central & Eastern Europe, Eurasia, Middle East and
Africa. Iskra has served on AstraZeneca's Senior Executive Team
since 2017.
As EVP, Vaccines & Immune Therapies, Iskra was responsible for
both the early and late-stage development of the Unit's pipeline
and portfolio, including COVID-19 and RSV vaccines and
monoclonal antibodies, strategic partnerships and acquisitions,
medical affairs and commercial operations.
Iskra has a PhD and an MBA in Business and Leadership from the
IEDC-Bled School of Management, Slovenia. She also holds a DMD from
the Medical University of Zagreb. She is a member of the Board of
Directors of myTomorrows, a global health technology company, and
Steering Committee of the Partnership for Health System
Sustainability and Resilience, a global collaboration dedicated to
improving patient outcomes.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Diseases, and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca's innovative
medicines are sold in more than 125 countries and used by millions
of patients worldwide. Please visit astrazeneca.com and
follow the Company on social media @AstraZeneca
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Date:
04 December 2024
|
|
By: /s/
Adrian Kemp
|
|
|
Name:
Adrian Kemp
|
|
|
Title:
Company Secretary
|
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
From Nov 2024 to Dec 2024
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
From Dec 2023 to Dec 2024
